Febuxostat tablet

By adopting chip packaging structure and compressed coating technology in febulistat/controlled release tablets, the problem of unstable drug release in the prior art is solved, and febulistat retention and slow release in the stomach are achieved, improving the Treatment effects and safety.

CN115297848BActive Publication Date: 2024-11-15JIANGSU HENGRUI MEDICINE CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202180019661.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-03-31
Filing Date
2021-03-31
Publication Date
2024-11-15
Estimated Expiration
2041-03-31

AI Technical Summary

Technical Problem

The existing febulista/controlled release tablets are difficult during the development process, especially the difficulty in keeping the drug concentration higher than 100 ng/mL within a predetermined time period, resulting in poor treatment effect and increasing the frequency of gout onset.

Method used

Using a chip-packing structure, which contains a febusterat chip-coated core coated on the coating layer. By adjusting the thickness and material combination of the coating layer, the drug remains in the stomach and is slowly released within a predetermined period of time, using pressed coating The technology and specific matrix materials combine to achieve controlled release effect.

Benefits of technology

The slow release of febulista within the predetermined time period is achieved, which improves the bioavailability of the drug, extends the maintenance time of effective blood drug concentration, reduces the frequency of gout attacks, and improves the safety and effectiveness of the treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure GPA0000326526750000181
    Figure GPA0000326526750000181
  • Figure GPA0000326526750000191
    Figure GPA0000326526750000191
  • Figure GPA0000326526750000201
    Figure GPA0000326526750000201
Patent Text Reader

Abstract

A sustained-release tablet comprises a tablet core containing an active drug, febuxostat, and a coating layer coated on the tablet core, wherein the tablet core is located in the coating layer, and the thickness of the coating layer on both sides of the tablet core in the Y-axis direction is at least one side less than the thickness of the coating layer in the X-axis direction, and the coating layer may contain a fast-release drug-containing coating layer of febuxostat outside the coating layer. The tablet can be used to treat gout, hyperuricemia and other diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present disclosure relates to a febuxostat tablet, which is a coated core tablet. The preparation comprises a tablet core containing a drug and a coating coated on the tablet core, and belongs to the field of pharmaceutical preparations. Background Art

[0002] Oral administration is a very advantageous route of drug delivery. Orally administered preparations are placed in the mouth and swallowed. Administration is simple, convenient, and painless, does not require any specialized equipment or the involvement of medical staff, has good patient compliance, and is low in cost.

[0003] Gastric emptying is part of the normal digestive process of the human body, which results in that drug formulations that enter the stomach via the oral route usually only stay in the stomach for a short time. The short gastric residence time limits the bioavailability of many types of orally administered drugs, especially drugs that act locally in the stomach, are preferentially absorbed in the upper gastrointestinal tract or absorbed in the environment of the lower gastrointestinal tract, and are unstable or have low solubility at neutral or alkaline pH. This type of drug can be delivered via gastric retentive formulations.

[0004] A sustained / controlled release tablet refers to a tablet that can release the drug at a predetermined rate and / or at a predetermined time after administration to maintain the required pharmacological activity within a required period of time. Such a preparation provides the drug to the body within a predetermined time period or at a predetermined absorption site, so that the drug level can be kept within the therapeutic range within a longer period of time relative to conventional (e.g., quick-release) preparations. The dosage form containing the core is a form of sustained / controlled release tablet, and the most commonly used material is a hydrophilic material, which, once in contact with a physiological medium, swells and becomes a colloid. When the dosage form is exposed to a physiological medium, the periphery will begin to hydrate and form a colloidal matrix, and as the medium continues to penetrate the dosage form, the thickness of the colloidal matrix increases. The drug is released by diffusion and / or erosion of the matrix.

[0005] Febuxostat is an oral non-purine xanthine oxidase (NP-SIXO) selective inhibitor developed by Teijin Pharma of Japan. It is mainly used for the chronic treatment of hyperuricemia in gout patients, the treatment of chronic hyperuricemia with urate deposition, and the treatment of hyperuricemia associated with cancer chemotherapy (tumor lysis syndrome). The main side effect is that it is often accompanied by acute gout attacks in the early stage of treatment, which increases the frequency of gout attacks and seriously affects the compliance of patients.

[0006] Patent application CN103210084A of Takeda Pharmaceutical discloses a novel composition containing febuxostat, including immediate release beads and sustained release beads containing febuxostat, which achieve sustained release effect by membrane control. The background technology of the application points out that febuxostat preparations that maintain a drug concentration above a critical concentration of 100 ng / mL for an extended period of time are expected to produce higher efficacy and will be a desired treatment option for controlling hyperuricemia, gout and many other disease states. However, the clinical project TMX-67XR involving the application was terminated for undisclosed reasons, which fully proves that there are great difficulties in the development of febuxostat sustained / controlled release tablets. Summary of the invention

[0007] The present invention provides a coated tablet, comprising a tablet core containing an active drug febuxostat, and a coating layer coated on the tablet core, wherein the tablet core is located in the coating layer, and the thickness of the coating layer on both sides of the tablet core in the Y-axis direction is at least one side less than the thickness of the coating layer in the X-axis direction (attached Figure 1 is a schematic diagram, in which the two sides of the core in the Y-axis direction correspond to the upper and lower surfaces in the figure respectively).

[0008] The coating thickness in the axial direction (the "Y" axis) along the direction of punch movement described in the present disclosure is determined by the amount of coating material added to the die and the punching force used when forming the tablet. The coating thickness along the "X" axis (perpendicular to the direction of punch movement) is determined by the kernel size, the position of the kernel in the die, and the diameter of the die.

[0009] The febuxostat tablet coating provided in the present invention provides an initial diameter sufficient to allow it to be retained in the stomach in the fed state. For example, a tablet with a diameter of about 12-18 mm can usually resist passing through the pyloric sphincter in the fed state. Specifically, the initial maximum diameter of the febuxostat tablet coating provided in the present invention can be 12-16 mm, and optionally 13-15 mm.

[0010] In an alternative embodiment, the chip package provided by the present disclosure is a gastric retentive chip package.

[0011] In an optional embodiment, the thickness of the coating layer on both sides of the tablet core in the Y-axis direction is the same or different. The thickness of the coating layer on one side of the tablet core can be 0.5-2.2 mm, optionally 1.0-2.0 mm, optionally 1.5-1.8 mm, or optionally 1.7-1.9 mm; the thickness of the coating layer on the other side of the tablet core can be 0.3-2.0 mm, optionally 0.8-1.8 mm, optionally 1.2-1.4 mm, or optionally 1.0-1.5 mm.

[0012] The coated core provided in the present disclosure, due to the special selection of coating thickness along the Y-axis direction, allows the active substance Febuxostat to be released in a predetermined delayed time period to achieve a controlled release effect, and the coating layer can be broken after being immersed in an aqueous medium for at least 1 hour to release the active substance, and can be broken after 1.5 hours or 2 hours, and the coating layer of the core provided in the present disclosure can be broken in an aqueous medium for no later than 4 hours. The investigation of the rupture time of the coating layer in an aqueous medium described in the present disclosure refers to the results of the investigation in 500 mL of pH4.5 PBS-0.5% SDS medium using a paddle method at 50 rpm.

[0013] For a given active drug, if the drug can be delivered almost completely to a specific absorption window in a controllable manner, or the release rate can be preferentially avoided or reduced in areas of the gastrointestinal tract where the active drug is more degraded or metabolized, in addition, delivering the active drug to the absorption window can increase the efficacy of the drug and / or reduce or eliminate side effects. Considering this aspect, if the coating layer ruptures too late, the absorption window may be missed. The coated chip provided in the present disclosure can rupture when the immersion time in the viscous medium is ≤6 hours to release the active substance, and can optionally rupture in ≤5 hours, or ≤4 hours. The investigation of the rupture time of the coating layer in the viscous medium described in the present disclosure refers to the use of a basket method at 75rpm, 500mL pH4.5PBS-2.5% HPMC K100LV medium for 2h, and then changing to 500ml 0.1MHCl-3% HPMC E5LV medium to continue the experiment, and investigate the rupture time in the viscous medium.

[0014] The coating layer described in the present disclosure is subjected to the dissolution and release determination method (Chinese Pharmacopoeia 2015 Edition Part IV General Rules 0931 Second Method), using 500 ml of 2.5% HPMC K100LV-pH6.0 phosphate buffer as the dissolution medium, the temperature is 37±0.5°C, the rotation speed is 150 revolutions per minute, and after 4 hours, the medium in each of the above dissolution cups is discarded, and then 900 ml of pH6.8 phosphate buffer preheated to 37±0.5°C is added to each dissolution cup, the rotation speed remains unchanged, and the operation is continued according to the method, and the cups are ruptured in 3-5 hours.

[0015] When the chip package is broken in the X-axis direction, the opening is too small and the depth is long (such as the attached Figure 6 As shown in the figure, the drug release is slow. Therefore, the coating thickness on both sides of the tablet core in the Y-axis direction is at least one side less than the coating thickness in the X-axis direction, so that the coating ruptures and releases the active drug in the Y-axis direction, ensuring the rapid release of the tablet core drug (as shown in the figure). Figure 2 shown).

[0016] In the present disclosure, the amount of the tablet core released during the delay period is no more than about 10% of the total amount of febuxostat in the tablet core, which should be understood as essentially no drug release from the tablet core, and the tablet core releases all or essentially all of the febuxostat in a very short period of time after the delay time expires. Specifically, within 1 hour after the coating layer ruptures, the amount of febuxostat released from the tablet core is more than 65% of the total amount of febuxostat in the tablet core, optionally more than 70%, and optionally more than 75%.

[0017] The core tablets disclosed herein are formed by compression-coating technology, which will be described in detail below. Compression-coated tablets are usually prepared by placing a portion of powdered or granular coating material in a die, compacting the portion of coating material into a dense state with a punch, placing the core on the dense coating material, and then introducing the remaining coating material into the die, applying pressure to form a coated tablet. With the innovation of compression technology, some technologies for preparing compression-coated tablets by one-step dry coating have also emerged, such as For details, see Yuichi Ozeki et al.'s study Evaluation of novel one-step dry-coated tablets as a platform for delayed-release tablets (Journal of Controlled Release 95 (2004) 51-60).

[0018] In the present disclosure, the hardness of the tablet core is relatively low, ensuring that the tablet core can expand after the aqueous medium contacts the tablet core, so that the outer coating is better broken, and the hardness of the tablet core is 10-120N, and 20-60N can be selected. In order to ensure the mechanical stability of the tablet core, so that it is sufficient to resist the pressure generated by the stomach, especially in the presence of food, to ensure that the integrity of the outer coating is not damaged, the hardness of the tablet is controlled at 120-300N, and 170-230N can be selected. In the present disclosure, the release of Febuxostat from the tablet core is not the result of the drug diffusing through the expanded coating material, but the result of physical rupture of the coating.

[0019] The coated core tablet provided by the present disclosure has a coating layer containing at least one matrix material, at least one hydrophobic plasticizer and at least one hydrophilic gel skeleton material, wherein the matrix material is an excipient that is insoluble or poorly soluble in water.

[0020] The hydrophobic plasticizer described in the optional embodiment can be selected from liquid paraffin, corn oil, castor oil, coconut oil, triacetin, monoacetin, dibutyl sebacate, dibutyl phthalate, long-chain fatty alcohols, long-chain fatty acids and their esters or salts thereof, behenic acid glyceryl, and behenic acid glyceryl can be selected. The content of the water-insoluble plasticizer is 0.1%-30% (mass percentage) of the total weight of the coating layer, and can be selected from 0.5%-20%, and can be selected from 1%-10%.

[0021] The plasticizer glyceryl behenate described in the present disclosure is a mixture of glycerol and behenic acid (a C 22 The ester formed by fatty acids (such as behenic acid) can be present in the form of its mono-, di- or tri-ester or a mixture thereof, and its HLB value can be less than 5, and can be about 2.

[0022] The applicant surprisingly found that the coating layer without a hydrophobic plasticizer was severely eroded in an aqueous medium, and it was difficult to maintain rigidity and integrity, and the coating layer could not play the role of delaying release after a period of time.

[0023] In an optional embodiment, the water-insoluble or poorly water-soluble excipient can be selected from any known water-insoluble cellulose derivatives, polymers, and mixtures of polyvinyl acetate and povidone, etc. The water-insoluble cellulose derivatives and polymers include alkyl celluloses such as ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose and their derivatives, polymethacrylic acid polymers, polyvinyl acetate and cellulose acetate polymers, fatty acids or their esters or salts, long-chain fatty alcohols, polyoxyethylene alkyl ethers, polyoxyethylene stearic acid, sugar esters, lauroyl macrogol-32 glycerol, stearoyl macrogol-32 glycerol, etc.

[0024] SR is a mixture of polyvinyl acetate and polyvinyl pyrrolidone. It is a material with very good plasticity and is particularly suitable for direct tableting.

[0025] In an alternative embodiment, the matrix material is selected from a combination of polymethacrylic acid polymer, polyvinyl acetate and a povidone mixture.

[0026] Optionally, the content of polymethacrylic acid polymer in the coating layer is 50%-90% (mass percentage) of the total weight of the coating layer, optionally 60%-85%, optionally 65%-75%, and the content of the mixture of vinyl acetate and povidone is 5%-40% (mass percentage) of the total weight of the coating layer, optionally 15%-25%.

[0027] In an optional embodiment, the matrix material is selected from a combination of Eudragit and a mixture of polyvinyl acetate and povidone.

[0028] In an optional embodiment, the content of Eudragit in the coating layer is 50%-90% (mass percentage), optionally 60%-85%, optionally 65%-75% of the total weight of the coating layer, and the content of the mixture of polyvinyl acetate and povidone is 5%-40% (mass percentage), optionally 15%-25% of the total weight of the coating layer.

[0029] In an optional embodiment, the matrix material is selected from a combination of Eudragit RL, Eudragit RS and a mixture of polyvinyl acetate and povidone. Eudragit RL and Eudragit RS are insoluble in water but can swell, thereby forming pores in the coating. The pore diameter of Eudragit RL is 1-5 μm, and the pore diameter of Eudragit RS is 0.1-0.6 μm.

[0030] In an optional embodiment, the content of Eudragit RL and Eudragit RS in the coating layer is 50%-90% (mass percentage), optionally 60%-85%, optionally 65%-75% of the total weight of the coating layer, and the content of the mixture of polyvinyl acetate and povidone is 5%-40% (mass percentage), optionally 15%-25% of the total weight of the coating layer.

[0031] In an optional embodiment, the matrix material is selected from a combination of Eudragit RLPO and Eudragit RSPO with a mixture of polyvinyl acetate and povidone.

[0032] In an optional embodiment, the content of Eudragit RLPO and Eudragit RSPO in the coating layer is 50%-90% (mass percentage), optionally 60%-85%, optionally 65%-75% of the total weight of the coating layer, and the content of the mixture of polyvinyl acetate and povidone is 5%-40% (mass percentage), optionally 15%-25% of the total weight of the coating layer.

[0033] In an optional embodiment, the matrix material is selected from Eudragit RLPO, Eudragit RSPO, SR combination.

[0034] In an optional embodiment, the content of Eudragit RLPO and Eudragit RSPO in the coating layer accounts for 50%-90% (mass percentage) of the total weight of the coating layer, optionally 60%-85%, optionally 65%-75%, The content of SR is 5%-40% (mass percentage) of the total weight of the coating layer, and can be optionally 15%-25%.

[0035] In an optional embodiment, the content of Eudragit RSPO in the coating layer is 5%-40% (mass percentage) of the total weight of the coating layer, optionally 10%-30%, optionally 15%-25%.

[0036] In an optional embodiment, the content of Eudragit RLPO in the coating layer accounts for 20%-80% (mass percentage) of the total weight of the coating layer, optionally 30%-70%, optionally 45%-55%.

[0037] In an optional embodiment, the content of Eudragit RSPO in the coating layer accounts for 5%-40% (mass percentage) of the total weight of the coating layer, and the content of Eudragit RLPO accounts for 20%-80% (mass percentage) of the total weight of the coating layer. The content of SR is 5%-40% (mass percentage) of the total weight of the coating layer.

[0038] In an optional embodiment, the content of Eudragit RSPO in the coating layer accounts for 10%-30% (mass percentage) of the total weight of the coating layer, and the content of Eudragit RLPO accounts for 30%-70% (mass percentage) of the total weight of the coating layer. The content of SR is 15%-25% (mass percentage) of the total weight of the coating layer.

[0039] In an optional embodiment, the content of Eudragit RSPO in the coating layer accounts for 15%-25% (mass percentage) of the total weight of the coating layer, and the content of Eudragit RLPO accounts for 45%-55% (mass percentage) of the total weight of the coating layer. The content of SR is 15%-25% (mass percentage) of the total weight of the coating layer.

[0040] The hydrophilic gel skeleton material described in the present disclosure is selected from methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxymethyl cellulose, sodium hydroxymethyl cellulose, chitin, deacetylated chitosan, galactomannan, pectin, sodium alginate, potassium alginate, agar, carrageenan, locust bean gum, etc.

[0041] In an optional embodiment, the hydrophilic gel skeleton material is hydroxypropyl methylcellulose, and the hydroxypropyl methylcellulose material is selected from materials with low weight average molecular weight and low viscosity, such as E-type methylcellulose.

[0042] The content of the hydrophilic gel skeleton material in the present disclosure is 1%-30% (mass percentage) of the total weight of the coating layer, optionally 5%-20%, optionally 8%-15%.

[0043] In an optional embodiment, the hydrophilic gel skeleton material is E-type hydroxypropyl methylcellulose, and its content is 1%-30% (mass percentage) of the total weight of the coating layer, optionally 5%-20%, and optionally 10%-15%.

[0044] In the present disclosure, in order to meet the requirements of the preparation process, the optional hydrophilic gel skeleton material can also be used as an adhesive.

[0045] The febuxostat coated core tablet provided by the present disclosure contains, in addition to the active substance febuxostat, a disintegrant of a rapid-release preparation known in the art. In the present disclosure, the disintegrant can be a material that effervesces and / or swells in the presence of an aqueous medium, thereby providing the necessary force to mechanically rupture the coating material. Specifically, the disintegrant can be selected from cross-linked sodium carboxymethyl cellulose, dry starch, low-substituted hydroxypropyl methylcellulose, sodium carboxymethyl starch and cross-linked polyvinylpyrrolidone, etc., and cross-linked sodium carboxymethyl cellulose can be selected. The amount of the disintegrant can be 2%-35% (mass percentage) of the weight of the core tablet, optionally 5%-25% of the weight of the core tablet, and optionally 8%-15% of the weight of the core tablet.

[0046] The febuxostat coated core tablet provided by the present disclosure may further contain a pharmaceutically acceptable water-soluble filler and / or a water-insoluble filler in the core tablet, wherein the water-soluble filler includes lactose, mannitol, sucrose, sorbitol, etc., and the water-insoluble filler includes starch, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, etc. The content of the diluent may be 1%-99% of the weight of the core tablet, (mass percentage) optionally 20%-85%, optionally 60%-80%.

[0047] In an optional embodiment, the filler of the tablet core is selected from a combination of a water-soluble filler and a water-insoluble filler, wherein the content of the water-soluble filler can be 35%-75% (mass percentage) of the tablet core weight, optionally 45%-70%, optionally 50%-65%; the content of the water-insoluble filler can be 1%-25% (mass percentage) of the tablet core weight, optionally 10%-25%.

[0048] In an alternative embodiment, the filler of the tablet core is a combination of lactose selected from the water-soluble fillers and microcrystalline cellulose selected from the water-insoluble fillers.

[0049] The febuxostat coated core tablet provided by the present disclosure may further contain a pharmaceutically acceptable binder in the core tablet, and the binder may be selected from at least one of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, trehalose and pullulan, but is not limited thereto. The content of the binder may be 1%-5% (mass percentage) of the total weight of the core tablet.

[0050] In an alternative embodiment, the binder is hydroxypropyl cellulose.

[0051] The tablet core may contain a suitable lubricant, such as colloidal silicon dioxide, talc, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol or sodium lauryl sulfate. The content of the lubricant in the tablet core is 0.5%-10% (mass percentage) of the total weight of the tablet core, and can be optionally 1%-5%.

[0052] In an alternative embodiment, the lubricant for the tablet core is magnesium stearate.

[0053] Appropriately, a colorant may be added to the tablet core to ensure that the tablet core is accurately positioned in the coating to ensure that the tablet has an appropriate coating thickness, so that the delay time is reproducible, thereby avoiding intra-subject and inter-patient differences in bioavailability. Appropriate colorants may be iron oxide, titanium dioxide, iron hydroxide, etc. The selection of colorants is not limited to the scope of the present disclosure. The content of the colorant is 0.1%-3% of the total weight of the tablet core, and 0.4%-1% may be selected.

[0054] In an optional embodiment, the febuxostat coated core provided by the present disclosure may further contain a hydrophilic gel skeleton material in the core, and the hydrophilic gel skeleton material is selected from cellulose derivatives, non-cellulose polysaccharides, natural gums, vinyl polymers or acrylic polymers, etc. The cellulose derivatives may be selected from methylcellulose, hydroxyethylcellulose, hydroxyethylmethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose and sodium hydroxymethylcellulose, etc.; the non-cellulose polysaccharides may be selected from glucose, chitin, deacetylated chitosan and galactomannan, etc.; the natural gums may be selected from pectin, sodium alginate, potassium alginate, agar, carrageenan, locust bean gum, gum aralia, etc.

[0055] In an optional embodiment, the febuxostat-coated core tablet provided by the present disclosure has a hydrophilic gel skeleton material in the core tablet that is a cellulose derivative.

[0056] In an optional embodiment, the febuxostat coated core tablet provided by the present disclosure, the hydrophilic gel skeleton material in the core tablet is selected from hydroxyethyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose.

[0057] In an optional embodiment, the hydrophilic gel matrix material in the core of the febuxostat-coated tablet provided by the present disclosure is hydroxypropyl methylcellulose.

[0058] In an optional embodiment, in the febuxostat coated core tablet provided by the present disclosure, the hydrophilic gel skeleton material in the tablet core accounts for 1%-20% of the total weight of the tablet core.

[0059] In an optional embodiment, in the febuxostat coated core tablet provided by the present disclosure, the hydrophilic gel skeleton material in the tablet core accounts for 2%-10% of the total weight of the tablet core.

[0060] In an optional embodiment, in the febuxostat coated core tablet provided by the present disclosure, the hydrophilic gel skeleton material in the tablet core accounts for 3%-8% of the total weight of the tablet core.

[0061] The present disclosure provides a febuxostat tablet, which contains not only the core tablet and the coating layer mentioned above, but also a rapid-release portion of febuxostat. The rapid-release portion can be completed by any technical means well known in the art, such as a double-layer tablet, a rapid-release coating, etc.

[0062] In an optional embodiment, the febuxostat tablets provided by the present disclosure have a sustained-release effect.

[0063] The present disclosure provides a febuxostat tablet, which contains the above-mentioned core tablet, and the coating layer of the core tablet contains a fast-release drug-containing coating layer of febuxostat.

[0064] In an optional embodiment, the immediate-release drug-containing coating layer of febuxostat contains the active drug febuxostat and a coating material. The coating material may be hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl alcohol, gastric-soluble Opadry, gastric-soluble Opadry, or Opadry (03K180007-CN).

[0065] Since the immediate-release component is rapidly released in the medium or in vivo, the drug release characteristics of the chip-coated tablets in the present disclosure are the same as those of the febuxostat tablets containing the immediate-release component.

[0066] In an optional embodiment, the content of febuxostat in the unit dosage form of the febuxostat tablet provided by the present disclosure is 1.1-1.8 times the content of febuxostat in the unit dosage form of Fibril, 1.2-1.6 times, or 1.5 times. Specifically, for example, the content of a single tablet of commercially available febuxostat is 20 mg, and the content of a single tablet of commercially available febuxostat is 30 mg, and the content of a single tablet of commercially available febuxostat is 40 mg, and the content of a unit tablet of febuxostat provided by the present disclosure is 60 mg. The increased drug dosage increases the rate of achieving the target of lowering uric acid, thereby reducing the frequency of gout attacks and ensuring the efficacy.

[0067] In an optional embodiment, the amount of febuxostat in the unit dosage form of the febuxostat tablet provided by the present disclosure is 10 mg-200 mg, optionally 20 mg-150 mg, and the optional amount of febuxostat is 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 mg. g, 110mg, 115mg, 120mg, 125mg, 130mg, 135mg, 140mg, 145mg, 150mg, 155mg, 160mg, 165mg, 170mg, 175mg, 180mg, 185mg, 190mg, 195mg, 200mg, 30mg and 60mg can be selected, the content ratio of the active substance in the rapid-release drug-containing coating layer and the tablet core is 1:10-10:1, and 1:5-5:1 can be selected.

[0068] In an optional embodiment, the febuxostat tablet contains the following ingredients:

[0069] Chip

[0070] Febuxostat

[0071] Lactose 50%-65% (mass percentage);

[0072] Microcrystalline cellulose 10%-25% (mass percentage);

[0073] Cross-linked sodium carboxymethyl cellulose 8%-15% (mass percentage);

[0074] Hydroxypropyl cellulose 1-5% (mass percentage);

[0075] Magnesium stearate 1%-5% (mass percentage), based on the total weight of the tablet core;

[0076] Coating layer

[0077] Eudragit RSPO 15%-25% (mass percentage);

[0078] Eudragit RLPO 45%-55% (mass percentage);

[0079] SR 15%-25% (mass percentage);

[0080] Hydroxypropyl methylcellulose 8%-15% (mass percentage), based on the total weight of the coating layer.

[0081] In an optional embodiment, the febuxostat tablet contains the following ingredients:

[0082] Chip

[0083] Febuxostat

[0084] Lactose 50%-65% (mass percentage);

[0085] Microcrystalline cellulose 10%-25% (mass percentage);

[0086] Cross-linked sodium carboxymethyl cellulose 8%-15% (mass percentage);

[0087] Hydroxypropyl cellulose 1-5% (mass percentage);

[0088] Magnesium stearate 1%-5% (mass percentage);

[0089] Hydroxypropyl methylcellulose 3%-8% (mass percentage), based on the total weight of the tablet core;

[0090] Coating layer

[0091] Eudragit RSPO 15%-25% (mass percentage);

[0092] Eudragit RLPO 45%-55% (mass percentage);

[0093] SR 15%-25% (mass percentage);

[0094] Hydroxypropyl methylcellulose 8%-15% (mass percentage), based on the total weight of the coating layer.

[0095] In an optional embodiment, the active substance content in the febuxostat tablets is 30 mg, wherein the content ratio of the active substance in the immediate-release drug-containing coating layer to the tablet core is 1:10-10:1, optionally 1:5-5:1, optionally 1:2-1:1, optionally 2:3.

[0096] In an optional embodiment, the active substance content in the febuxostat tablets is 60 mg, wherein the content ratio of the active substance in the immediate-release drug-containing coating layer to the tablet core is 1:10-10:1, optionally 1:5-5:1, optionally 1:3-1:1, optionally 3:7.

[0097] Optionally, there is an isolation layer between the coating layer and the febuxostat immediate-release layer, and the isolation layer is a thin layer of polymer material, forming a film-like coating layer, which increases the tablet weight by 1%-50% (mass percentage), and optionally 2%-4%.

[0098] The material of the isolation layer can be selected from one or more of hydroxypropyl methylcellulose, povidone, copovidone, hydroxypropyl cellulose and gastric soluble Opadry, gastric soluble Opadry can be selected, and gastric soluble Opadry (YS-1-7027-CN) can be selected.

[0099] In an optional embodiment, the Febuxostat tablets provided by the present disclosure have an AUC (geometric mean) that is basically equivalent to that of Febuxostat, and significantly prolong the maintenance time of effective blood drug concentration, thereby improving effectiveness, wherein basically equivalent means that the AUC ratio is in the range of 85%-135%.

[0100] The febuxostat tablets provided by the present disclosure significantly prolong the maintenance time of effective blood drug concentration and reduce the Cmax value, thereby improving safety.

[0101] For the Febuxostat tablets provided by the present disclosure, when a subject takes the Febuxostat tablets provided by the present disclosure once a day, the maintenance time of the blood drug concentration (geometric mean) ≥ 100 ng / ml is 1-3 times that of the subject taking Febuxostat once a day, and can be optionally 1.25-2.0 times.

[0102] For the febuxostat tablets provided by the present disclosure, after the subject consumes a low-fat, low-calorie meal (fat provides about 10% of the calories in the food, and the total calories are about 300 kcal), the blood drug concentration of ≥100 ng / ml is maintained for at least 10 hours, optionally at least 12 hours, and optionally at least 15 hours.

[0103] For the febuxostat tablets provided in the present disclosure, after a subject has consumed a standard meal, the blood drug concentration of ≥100 ng / ml is maintained for at least 12 hours, optionally at least 15 hours, and optionally at least 17 hours.

[0104] The blood drug concentrations described in this disclosure refer to geometric means.

[0105] The febuxostat tablets provided by the present disclosure provide distinct double peaks in vivo.

[0106] For the Febuxostat tablets provided in the present disclosure, the time for the blood drug concentration of a subject to recover after taking the drug is 2-5 hours, and can be optionally 3-4 hours.

[0107] The febuxostat tablets provided in the present disclosure have a rupture time in the body of a subject of 2-5 hours after administration, and can be optionally 3-4 hours.

[0108] The present disclosure provides a use of the above-mentioned febuxostat tablets in preparing a medicament for treating gout, hyperuricemia, prostatitis, inflammatory bowel disease, prolonged QT interval, myocardial infarction, cardiac hypertrophy, hypertension, nephrolithiasis, chronic kidney disease, metabolic syndrome, diabetes, diabetic nephropathy, and congestive heart failure.

[0109] The present disclosure provides a method for treating gout, hyperuricemia, prostatitis, inflammatory bowel disease, prolonged QT interval, myocardial infarction, cardiac hypertrophy, hypertension, nephrolithiasis, chronic kidney disease, metabolic syndrome, diabetes, diabetic nephropathy, and congestive heart failure, by administering the above-mentioned Febuxostat tablets provided by the present disclosure to a patient.

[0110] The present disclosure provides a method for preparing the above-mentioned febuxostat tablets, which comprises the following steps: granulating febuxostat and optional tablet core excipients into first particles; making the first particles into tablet cores; granulating the coating layer excipients into second particles; compressing and coating the second particles around the tablet core; and coating the immediate release layer.

[0111] In an optional embodiment, the method includes the following steps: granulating Febuxostat with a filler, a binder, and a portion of a disintegrant, and compressing the tablet core after mixing with the remaining disintegrant and lubricant; granulating the coating layer excipients containing a matrix material, a water-insoluble plasticizer, and a hydrophilic gel skeleton material; compressing the core tablets; and coating the immediate-release layer.

[0112] In an optional embodiment, the method includes the following steps: granulating febuxostat with lactose, microcrystalline cellulose, hydroxypropyl cellulose and a portion of cross-linked sodium carboxymethyl cellulose, mixing with the remaining cross-linked sodium carboxymethyl cellulose and magnesium stearate, and then compressing the tablet core; granulating Eudragit RSPO, Eudragit RLPO, glyceryl behenate and a portion of hypromellose, mixing with Kollidon SR and the remaining hypromellose, and then compressing the core tablet; and coating the immediate release layer.

[0113] In an optional embodiment, the method includes the following steps: granulating febuxostat with lactose, microcrystalline cellulose, hydroxypropyl cellulose and part of cross-linked sodium carboxymethyl cellulose, mixing with the remaining cross-linked sodium carboxymethyl cellulose and magnesium stearate, and then pressing the tablet core; granulating Eudragit RSPO, Eudragit RLPO, glyceryl behenate and part of hypromellose, mixing with Kollidon SR and the remaining hypromellose, and then pressing the core tablet; coating with Opadry isolation layer; coating with Opadry and febuxostat immediate release layer.

[0114] Optionally, the method for preparing febuxostat tablets comprises a film coating step after the preparation of the core tablets is completed.

[0115] On the other hand, the present disclosure provides a febuxostat tablet, comprising a tablet core containing an active drug febuxostat, and a coating layer coated on the tablet core, wherein the tablet core is located in the coating layer, and the tablet core also contains a hydrophilic gel skeleton material accounting for 1%-20% of the total weight of the tablet core; the coating layer contains at least one matrix material, at least one hydrophobic plasticizer and at least one hydrophilic gel skeleton material, and further includes a rapid-release component containing the active substance febuxostat.

[0116] In an optional embodiment, the hydrophilic gel skeleton material of the tablet core is selected from cellulose derivatives, non-cellulose polysaccharides, natural gums, vinyl polymers or acrylic polymers, etc.; the cellulose derivatives can be selected from methyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxymethyl cellulose and sodium hydroxymethyl cellulose, etc.; the non-cellulose polysaccharides are selected from glucose, chitin, deacetylated chitosan and galactomannan, etc.; the natural gum is selected from pectin, sodium alginate, potassium alginate, agar, carrageenan, locust bean gum, claw ear gum, etc.

[0117] In an optional embodiment, in the febuxostat tablet provided by the present disclosure, the hydrophilic gel skeleton material in the tablet core is a cellulose derivative.

[0118] In an optional embodiment, the febuxostat coated core tablet provided by the present disclosure, the hydrophilic gel skeleton material in the core tablet is selected from hydroxyethyl methylcellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose.

[0119] In an optional embodiment, in the febuxostat tablet provided by the present disclosure, the hydrophilic gel matrix material in the tablet core is hydroxypropyl methylcellulose.

[0120] In an optional embodiment, in the febuxostat tablets provided by the present disclosure, the hydrophilic gel matrix material in the tablet core accounts for 2%-10% of the total weight of the tablet core.

[0121] In an optional embodiment, in the febuxostat tablets provided by the present disclosure, the hydrophilic gel skeleton material in the tablet core accounts for 3%-8% of the total weight of the tablet core.

[0122] In an optional embodiment, the hydrophobic plasticizer may be selected from liquid paraffin, corn oil, castor oil, coconut oil, triacetin, monoacetin, dibutyl sebacate, dibutyl phthalate, long-chain fatty alcohols, long-chain fatty acids and their esters or salts thereof, behenic acid glyceryl, and behenic acid glyceryl may be selected. The content of the water-insoluble plasticizer is 0.1%-30% (mass percentage) of the total weight of the coating layer, and may be selected from 0.5%-20%, and may be selected from 1%-10%.

[0123] The plasticizer glyceryl behenate described in the present disclosure is a mixture of glycerol and behenic acid (a C 22 The ester formed by fatty acids (such as behenic acid) can be present in the form of its mono-, di- or tri-ester or a mixture thereof, and its HLB value can be less than 5, and can be about 2.

[0124] The applicant surprisingly found that the coating layer without a hydrophobic plasticizer was severely eroded in an aqueous medium, and it was difficult to maintain rigidity and integrity, and the coating layer could not play the role of delaying release after a period of time.

[0125] In an optional embodiment, the water-insoluble or poorly water-soluble excipient can be selected from any known water-insoluble cellulose derivatives, polymers, and mixtures of polyvinyl acetate and povidone, etc. The water-insoluble cellulose derivatives and polymers include alkyl celluloses such as ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, carboxymethyl cellulose and their derivatives, polymethacrylic acid polymers, polyvinyl acetate and cellulose acetate polymers, fatty acids or their esters or salts, long-chain fatty alcohols, polyoxyethylene alkyl ethers, polyoxyethylene stearic acid, sugar esters, lauroyl macrogol-32 glycerol, stearoyl macrogol-32 glycerol, etc.

[0126] In an alternative embodiment, the matrix material is selected from a combination of polymethacrylic acid polymer, polyvinyl acetate and a povidone mixture.

[0127] In an optional embodiment, the content of polymethacrylic acid polymer in the coating layer is 50%-90% (mass percentage), optionally 60%-85%, optionally 65%-75% of the total weight of the coating layer, and the content of the mixture of vinyl acetate and povidone is 5%-40% (mass percentage), optionally 15%-25% of the total weight of the coating layer.

[0128] In an optional embodiment, the matrix material is selected from a combination of Eudragit and a mixture of polyvinyl acetate and povidone.

[0129] In an optional embodiment, the content of Eudragit in the coating layer is 50%-90% (mass percentage), optionally 60%-85%, optionally 65%-75% of the total weight of the coating layer, and the content of the mixture of polyvinyl acetate and povidone is 5%-40% (mass percentage), optionally 15%-25% of the total weight of the coating layer.

[0130] In an optional embodiment, the matrix material is selected from a combination of Eudragit RL, Eudragit RS and a mixture of polyvinyl acetate and povidone. Eudragit RL and Eudragit RS are insoluble in water but can swell, thereby forming pores in the coating. The pore diameter of Eudragit RL is 1-5 μm, and the pore diameter of Eudragit RS is 0.1-0.6 μm.

[0131] In an optional embodiment, the content of Eudragit RL and Eudragit RS in the coating layer is 50%-90% (mass percentage), optionally 60%-85%, optionally 65%-75% of the total weight of the coating layer, and the content of the mixture of polyvinyl acetate and povidone is 5%-40% (mass percentage), optionally 15%-25% of the total weight of the coating layer.

[0132] In an optional embodiment, the matrix material is selected from a combination of Eudragit RLPO and Eudragit RSPO with a mixture of polyvinyl acetate and povidone.

[0133] In an optional embodiment, the content of Eudragit RLPO and Eudragit RSPO in the coating layer is 50%-90% (mass percentage), optionally 60%-85%, optionally 65%-75% of the total weight of the coating layer, and the content of the mixture of polyvinyl acetate and povidone is 5%-40% (mass percentage), optionally 15%-25% of the total weight of the coating layer.

[0134] In an optional embodiment, the matrix material is selected from Eudragit RLPO, Eudragit RSPO, SR combination.

[0135] In an optional embodiment, the content of Eudragit RLPO and Eudragit RSPO in the coating layer accounts for 50%-90% (mass percentage) of the total weight of the coating layer, optionally 60%-85%, optionally 65%-75%, The content of SR is 5%-40% (mass percentage) of the total weight of the coating layer, and can be optionally 15%-25%.

[0136] In an optional embodiment, the content of Eudragit RSPO in the coating layer is 5%-40% (mass percentage) of the total weight of the coating layer, optionally 10%-30%, optionally 15%-25%.

[0137] In an optional embodiment, the content of Eudragit RLPO in the coating layer accounts for 20%-80% (mass percentage) of the total weight of the coating layer, optionally 30%-70%, optionally 45%-55%.

[0138] In an optional embodiment, the content of Eudragit RSPO in the coating layer accounts for 5%-40% (mass percentage) of the total weight of the coating layer, and the content of Eudragit RLPO accounts for 20%-80% (mass percentage) of the total weight of the coating layer. The content of SR is 5%-40% (mass percentage) of the total weight of the coating layer.

[0139] In an optional embodiment, the content of Eudragit RSPO in the coating layer accounts for 10%-30% (mass percentage) of the total weight of the coating layer, and the content of Eudragit RLPO accounts for 30%-70% (mass percentage) of the total weight of the coating layer. The content of SR is 15%-25% (mass percentage) of the total weight of the coating layer.

[0140] In an optional embodiment, the content of Eudragit RSPO in the coating layer accounts for 15%-25% (mass percentage) of the total weight of the coating layer, and the content of Eudragit RLPO accounts for 45%-55% (mass percentage) of the total weight of the coating layer. The content of SR is 15%-25% (mass percentage) of the total weight of the coating layer.

[0141] In an optional embodiment, the hydrophilic gel matrix material in the coating layer is selected from methyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxymethyl cellulose, sodium hydroxymethyl cellulose, chitin, deacetylated chitosan, galactomannan, pectin, sodium alginate, potassium alginate, agar, carrageenan, locust bean gum, etc.

[0142] In an optional embodiment, the hydrophilic gel matrix material in the coating layer is hydroxypropyl methylcellulose, and the hydroxypropyl methylcellulose material is selected from materials with low weight average molecular weight and low viscosity, such as E-type methylcellulose.

[0143] In an optional embodiment, the content of the hydrophilic gel skeleton material in the coating layer of the present disclosure is 1%-30% (mass percentage) of the total weight of the coating layer, optionally 5%-20%, optionally 8%-15%.

[0144] In an optional embodiment, the hydrophilic gel skeleton material is E-type hydroxypropyl methylcellulose, and its content is 1%-30% (mass percentage) of the total weight of the coating layer, optionally 5%-20%, and optionally 8%-15%.

[0145] In the present disclosure, in order to meet the requirements of the preparation process, the optional hydrophilic gel skeleton material can also be used as an adhesive.

[0146] The febuxostat tablets provided in the present disclosure contain, in addition to the active substance febuxostat, a disintegrant of a rapid-release preparation known in the art in the tablet core. In the present disclosure, the disintegrant may be a material that effervesces and / or swells in the presence of an aqueous medium, thereby providing the necessary force to mechanically rupture the coating material. Specifically, the disintegrant may be selected from cross-linked sodium carboxymethyl cellulose, dry starch, low-substituted hydroxypropyl methylcellulose, sodium carboxymethyl starch, and cross-linked polyvinylpyrrolidone, etc., and cross-linked sodium carboxymethyl cellulose may be selected. The amount of the disintegrant may be 2%-35% (mass percentage) of the tablet core weight, optionally 5%-25% of the tablet core weight, and optionally 8%-15% of the tablet core weight.

[0147] The febuxostat tablets provided by the present disclosure may further contain a pharmaceutically acceptable water-soluble filler and / or a water-insoluble filler in the tablet core. The water-soluble filler includes lactose, mannitol, sucrose, sorbitol, etc., and the water-insoluble filler includes starch, microcrystalline cellulose, calcium sulfate, calcium hydrogen phosphate, etc. The content of the diluent may be 1%-99% of the tablet core weight (mass percentage), optionally 20%-85%, and optionally 60%-80%.

[0148] In an optional embodiment, the filler of the tablet core is selected from a combination of a water-soluble filler and a water-insoluble filler, wherein the content of the water-soluble filler can be 35%-75% (mass percentage) of the tablet core weight, optionally 45%-70%, optionally 50%-65%; the content of the water-insoluble filler can be 1%-30% (mass percentage) of the tablet core weight, optionally 10%-25%.

[0149] In an alternative embodiment, the filler of the tablet core is a combination of lactose selected from the water-soluble fillers and microcrystalline cellulose selected from the water-insoluble fillers.

[0150] The febuxostat tablets provided in the present disclosure may further contain a pharmaceutically acceptable binder in the tablet core. The binder may be selected from at least one of hydroxypropyl cellulose, hydroxypropyl methyl cellulose, polyvinyl pyrrolidone, methyl cellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, trehalose and pullulan, but is not limited thereto. The content of the binder may be 1%-5% (mass percentage) of the total weight of the tablet core.

[0151] In an alternative embodiment, the binder is hydroxypropyl cellulose.

[0152] The tablet core may contain a suitable lubricant, such as colloidal silicon dioxide, talc, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol or sodium lauryl sulfate. The content of the lubricant in the tablet core is 0.5%-10% (mass percentage) of the total weight of the tablet core, and can be optionally 1%-5%.

[0153] In an alternative embodiment, the lubricant for the tablet core is magnesium stearate.

[0154] Appropriately, a colorant may be added to the tablet core to ensure that the tablet core is accurately positioned in the coating to ensure that the tablet has an appropriate coating thickness, so that the delay time is reproducible, thereby avoiding intra-subject and inter-patient differences in bioavailability. Appropriate colorants may be iron oxide, titanium dioxide, iron hydroxide, etc. The selection of colorants is not limited to the scope of the present disclosure. The content of the colorant is 0.1%-3% of the total weight of the tablet core, and 0.4%-1% may be selected.

[0155] The febuxostat tablets provided in the present disclosure provide an initial diameter sufficient to allow them to be retained in the stomach in the fed state. For example, a tablet with a diameter of about 12-18 mm can usually resist passing through the pyloric sphincter in the fed state. Specifically, the initial maximum diameter of the febuxostat-coated core tablets of the present disclosure can be 12-16 mm, and optionally 13-15 mm.

[0156] In an alternative embodiment, the febuxostat tablet provided by the present disclosure is a gastric retention tablet.

[0157] In the present disclosure, the hardness of the tablet core is relatively low, ensuring that the tablet core can expand after the aqueous medium contacts the tablet core, so that the outer coating is better broken, and the hardness of the tablet core is 10-120N, and 20-60N can be selected. In order to ensure the mechanical stability of the tablet core, so that it is sufficient to resist the pressure generated by the stomach, especially in the presence of food, to ensure that the integrity of the outer coating is not damaged, the hardness of the tablet is controlled at 30-250N, and 70-180N can be selected. In the present disclosure, the release of Febuxostat from the tablet core is not the result of the drug diffusing through the expanded coating material, but the result of physical rupture of the coating.

[0158] In an optional embodiment, the febuxostat tablets provided by the present disclosure have a sustained-release effect.

[0159] In an optional embodiment, the present disclosure provides a febuxostat tablet in which the immediate-release component is an immediate-release drug-containing coating layer.

[0160] In an optional embodiment, the immediate-release drug-containing coating layer of febuxostat contains the active drug febuxostat and a coating material. The coating material may be hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl alcohol, gastric-soluble Opadry, gastric-soluble Opadry, or Opadry (03K180007-CN).

[0161] In an optional embodiment, the content of febuxostat in the unit dosage form of the febuxostat tablet provided by the present disclosure is 1.1-1.8 times the content of febuxostat in the unit dosage form of Fibril, 1.2-1.6 times, or 1.5 times. Specifically, for example, the content of a single tablet of commercially available febuxostat is 20 mg, and the content of a single tablet of commercially available febuxostat is 30 mg, and the content of a single tablet of commercially available febuxostat is 40 mg, and the content of a unit tablet of febuxostat provided by the present disclosure is 60 mg. The increased drug dosage increases the rate of achieving the target of lowering uric acid, thereby reducing the frequency of gout attacks and ensuring the efficacy.

[0162] In an optional embodiment, the amount of febuxostat in the unit dosage form of the febuxostat tablet provided by the present disclosure is 10 mg-200 mg, optionally 20 mg-150 mg, and the optional amount of febuxostat is 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 105 The invention relates to a pharmaceutical composition of the present invention to a pharmaceutically acceptable salt of at least one embodiment of the present invention. The pharmaceutical composition can be modified from a pharmaceutically acceptable salt to a acceptable salt. The pharmaceutical composition can be modified from a pharmaceutically acceptable salt to a acceptable salt.

[0163] In an optional embodiment, the febuxostat tablet contains the following ingredients:

[0164] Chip

[0165] Febuxostat

[0166] Lactose 50%-65% (mass percentage);

[0167] Microcrystalline cellulose 10%-25% (mass percentage);

[0168] Cross-linked sodium carboxymethyl cellulose 8%-15% (mass percentage);

[0169] Hydroxypropyl cellulose 1-5% (mass percentage);

[0170] Hydroxypropyl methylcellulose 3%-8% (mass percentage);

[0171] Magnesium stearate 1%-5% (mass percentage), based on the total weight of the tablet core;

[0172] Coating layer

[0173] Eudragit RSPO 15%-25% (mass percentage);

[0174] Eudragit RLPO 45%-55% (mass percentage);

[0175] SR 15%-25% (mass percentage);

[0176] Hydroxypropyl methylcellulose 8%-15% (mass percentage), based on the total weight of the coating layer.

[0177] In an optional embodiment, the active substance content in the febuxostat tablets is 30 mg, wherein the content ratio of the active substance in the immediate-release drug-containing coating layer to the tablet core is 1:10-10:1, optionally 1:5-5:1, optionally 1:2-1:1, optionally 2:3.

[0178] In an optional embodiment, the active substance content in the febuxostat tablets is 60 mg, wherein the content ratio of the active substance in the immediate-release drug-containing coating layer to the tablet core is 1:10-10:1, optionally 1:5-5:1, optionally 1:3-1:1, optionally 3:7.

[0179] Optionally, there is an isolation layer between the coating layer and the febuxostat immediate-release layer, and the isolation layer is a thin layer of polymer material, forming a film-like coating layer, which increases the tablet weight by 1%-50% (mass percentage), and optionally 2%-4%.

[0180] The material of the isolation layer can be selected from one or more of hydroxypropyl methylcellulose, povidone, copovidone, hydroxypropyl cellulose and gastric soluble Opadry, gastric soluble Opadry can be selected, and gastric soluble Opadry (YS-1-7027-CN) can be selected.

[0181] The Febuxostat tablets provided in the present disclosure release the active substance Febuxostat in a predetermined delayed time period to achieve a controlled release effect. The coating layer can be broken after being immersed in an aqueous medium for at least 1 hour to release the active substance, and can be broken after 1.5 hours or 2 hours. The coating layer of the tablet provided in the present disclosure has a rupture time in an aqueous medium of no later than 4 hours. The investigation of the rupture time of the coating layer in an aqueous medium described in the present disclosure refers to the results of the investigation in 500 mL of a pH 4.5 PBS-0.5% SDS medium using a paddle method at 50 rpm.

[0182] For a given active drug, if the drug can be delivered almost completely to a specific absorption window in a controllable manner, or the release rate can be preferentially avoided or reduced in areas of the gastrointestinal tract where the active drug is more degraded or metabolized, in addition, delivering the active drug to the absorption window can increase the efficacy of the drug and / or reduce or eliminate side effects. Considering this aspect, if the coating layer ruptures too late, the absorption window may be missed. The coated chip provided in the present disclosure can rupture when the immersion time in the viscous medium is ≤6 hours to release the active substance, and can optionally rupture in ≤5 hours, and optionally rupture in ≤4 hours. The investigation of the rupture time of the coating layer in the viscous medium described in the present disclosure refers to the use of a basket method at 75rpm, 500mL pH4.5 PBS -2.5% HPMC K100LV medium for 2h, and then changing to 500ml 0.1MHCl-3% HPMC E5LV medium to continue the experiment, and investigate the rupture time in the viscous medium.

[0183] The coating layer described in the present disclosure is subjected to the dissolution and release determination method (Chinese Pharmacopoeia 2015 Edition Part IV General Rules 0931 Second Method), using 500 ml of 2.5% HPMC K100LV-pH6.0 phosphate buffer as the dissolution medium, the temperature is 37±0.5°C, the rotation speed is 150 revolutions per minute, and after 4 hours, the medium in each of the above dissolution cups is discarded, and then 900 ml of pH6.8 phosphate buffer preheated to 37±0.5°C is added to each dissolution cup, the rotation speed remains unchanged, and the operation is continued according to the method, and the cups are ruptured in 3-5 hours.

[0184] In the present disclosure, the amount of the tablet core released during the delay period is no more than about 10% of the total amount of febuxostat in the tablet core, which should be understood as essentially no drug release from the tablet core, and the tablet core releases all or essentially all of the febuxostat in a very short period of time after the delay time expires. Specifically, within 1 hour after the coating layer ruptures, the amount of febuxostat released from the tablet core is more than 65% of the total amount of febuxostat in the tablet core, optionally more than 70%, and optionally more than 75%.

[0185] In an optional embodiment, the Febuxostat tablets provided by the present disclosure have an AUC (geometric mean) that is basically equivalent to that of Febuxostat, and significantly prolong the maintenance time of effective blood drug concentration, thereby improving effectiveness, wherein basically equivalent means that the AUC ratio is in the range of 85%-135%.

[0186] The febuxostat tablets provided by the present disclosure significantly prolong the maintenance time of effective blood drug concentration and reduce the Cmax value, thereby improving safety.

[0187] For the Febuxostat tablets provided by the present disclosure, when a subject takes the Febuxostat tablets provided by the present disclosure once a day, the maintenance time of the blood drug concentration (geometric mean) ≥ 100 ng / ml is 1-3 times that of the subject taking Febuxostat once a day, and can be optionally 1.25-2.0 times.

[0188] For the febuxostat tablets provided in the present disclosure, after a subject consumes a medium-fat dinner, the blood drug concentration of ≥100 ng / ml is maintained for at least 10 hours, optionally at least 12 hours, and optionally at least 15 hours.

[0189] For the Febuxostat tablets provided in the present disclosure, the time for the blood drug concentration of a subject to recover after taking the drug is 2-5 hours, and can be optionally 3-4 hours.

[0190] The febuxostat tablets provided in the present disclosure have a rupture time in the body of a subject of 2-5 hours after administration, and can be optionally 3-4 hours.

[0191] The present disclosure provides a use of the above-mentioned febuxostat tablets in preparing a medicament for treating gout, hyperuricemia, prostatitis, inflammatory bowel disease, prolonged QT interval, myocardial infarction, cardiac hypertrophy, hypertension, nephrolithiasis, chronic kidney disease, metabolic syndrome, diabetes, diabetic nephropathy, and congestive heart failure.

[0192] The present disclosure provides a method for treating gout, hyperuricemia, prostatitis, inflammatory bowel disease, prolonged QT interval, myocardial infarction, cardiac hypertrophy, hypertension, nephrolithiasis, chronic kidney disease, metabolic syndrome, diabetes, diabetic nephropathy, and congestive heart failure, by administering the above-mentioned Febuxostat tablets provided by the present disclosure to a patient.

[0193] The present disclosure provides a method for preparing the above-mentioned febuxostat tablets, which comprises the following steps: granulating febuxostat and optional tablet core excipients into first particles; making the first particles into tablet cores; granulating the coating layer excipients into second particles; compressing and coating the second particles around the tablet core; and coating the immediate release layer.

[0194] In an optional embodiment, the method includes the following steps: granulating Febuxostat with a filler, a binder, and a portion of a disintegrant, and compressing the tablet core after mixing with the hydrophilic gel skeleton material in the tablet core, the remaining disintegrant, and a lubricant; granulating the coating layer excipients containing a matrix material, a water-insoluble plasticizer, and a hydrophilic gel skeleton material; compressing the core tablet; and coating the immediate-release layer.

[0195] In an optional embodiment, the method includes the following steps: granulating febuxostat with lactose, microcrystalline cellulose, hydroxypropyl cellulose and part of cross-linked sodium carboxymethyl cellulose, mixing with hydroxypropyl methylcellulose, the remaining cross-linked sodium carboxymethyl cellulose and magnesium stearate, and then compressing the tablet core; granulating Eudragit RSPO, Eudragit RLPO, glyceryl behenate and part of hydropropyl methylcellulose, mixing with Kollidon SR and the remaining hydropropyl methylcellulose, and then compressing the core tablet; and coating the immediate release layer.

[0196] In an optional embodiment, the method includes the following steps: granulating febuxostat with lactose, microcrystalline cellulose, hydroxypropyl cellulose base and part of cross-linked sodium carboxymethyl cellulose, mixing with hydroxypropyl methylcellulose, the remaining cross-linked sodium carboxymethyl cellulose and magnesium stearate, and then pressing the tablet core; granulating Eudragit RSPO, Eudragit RLPO, glyceryl behenate and part of hydropropyl methylcellulose, mixing with Kollidon SR and the remaining hydropropyl methylcellulose, and then pressing the core tablet; coating with Opadry isolation layer; coating with Opadry and febuxostat immediate release layer.

[0197] Optionally, the method for preparing febuxostat tablets comprises a film coating step after the preparation of the core tablets is completed.

[0198] The present invention provides a method for treating gout, hyperuricemia, prostatitis, inflammatory bowel disease, prolonged QT interval, myocardial infarction, cardiac hypertrophy, hypertension, nephrolithiasis, chronic kidney disease, metabolic syndrome, diabetes, diabetic nephropathy, and congestive heart failure, wherein a febuxostat tablet containing 30 mg of febuxostat or a febuxostat tablet containing 60 mg of febuxostat is administered to the patient after a medium-fat dinner, and the administration is performed once a day.

[0199] The present invention provides a method for treating gout, hyperuricemia, prostatitis, inflammatory bowel disease, QT interval prolongation, myocardial infarction, cardiac hypertrophy, hypertension, nephrolithiasis, chronic kidney disease, metabolic syndrome, diabetes, diabetic nephropathy, and congestive heart failure. The patient is given febuxostat tablets containing 30 mg of febuxostat after a medium-fat dinner, and the average blood drug concentration is maintained at ≥100 ng / ml for at least 10 hours.

[0200] The present invention provides a method for treating gout, hyperuricemia, prostatitis, inflammatory bowel disease, QT interval prolongation, myocardial infarction, cardiac hypertrophy, hypertension, nephrolithiasis, chronic kidney disease, metabolic syndrome, diabetes, diabetic nephropathy, and congestive heart failure. The patient is given febuxostat tablets containing 60 mg of febuxostat after a medium-fat dinner, and the average blood drug concentration is maintained at ≥100 ng / ml for at least 15 hours.

[0201] In some embodiments, a febuxostat tablet containing 60 mg of febuxostat is administered to a patient after a moderate-fat dinner, and the mean blood drug concentration is maintained at ≥ 100 ng / ml for at least 18 hours. BRIEF DESCRIPTION OF THE DRAWINGS

[0202] Figure 1 .Schematic diagram of the package chip and the X-axis and Y-axis;

[0203] Figure 2 .Schematic diagram of chip rupture;

[0204] Figure 3. In vitro dissolution curves of two batches of samples with a specification of 30 mg;

[0205] Figure 4 . In vitro dissolution curves of two batches of samples with a specification of 60 mg;

[0206] Figure 5 .Average drug concentration-time logarithmic graph after a single oral administration of 60 mg*4 febuxostat sustained-release tablets or 40 mg*4 febuxostat tablets to Beagle dogs (full stomach, administration 1 hour after feeding).

[0207] Figure 6 .Schematic diagram of the small opening of the chip package. DETAILED DESCRIPTION

[0208] The contents of the present disclosure are further described in detail below through specific embodiments, but this should not be construed as limiting the scope of the above subject matter of the present disclosure to the following examples.

[0209] Example 1. Preparation of Febuxostat Tablets (Prescription 1)

[0210] Table 1. Preparation of 60 mg and 30 mg febuxostat tablets

[0211]

[0212]

[0213] 1. Preparation method:

[0214] 1) Tablet preparation (2000 tablets)

[0215] Accurately weigh various raw materials and auxiliary materials according to the prescribed amount, weigh the prescribed amount of adhesive hydroxypropyl cellulose (SL) and add it to the weighed purified water under stirring to prepare a 5% aqueous solution, mix the prescribed amount of febuxostat, microcrystalline cellulose (MCC Type 101), lactose, cross-linked carboxymethyl cellulose sodium (CC-Na), and yellow ferric oxide in a fluidized bed, use the 5% solution of the prescribed amount of hydroxypropyl cellulose (SL) as an adhesive, granulate, and dry. Add the granulated particles and the additional auxiliary materials cross-linked carboxymethyl cellulose sodium and magnesium stearate converted according to the yield into a mixing tank for mixing, use a STYL'One single punch tablet press (punch die 10.0mm shallow concave punch, R = 24.75mm) for tableting, and control the tablet hardness to 20-60N.

[0216] 2) Preparation of outer layer

[0217] Weigh the prescribed amount of Hydroxypropyl Methylcellulose E5LV and add it to purified water under stirring to prepare a 5% aqueous solution. Place the prescribed amount of Eudragit RSPO, Eudragit RLPO and Glyceryl Behenate in a fluidized bed with a 5% solution of HPMC E5LV as a binder, granulate and dry. After conversion according to the yield, add the additional excipients Kollidon SR and HPMC E5LV into a mixing tank for total mixing.

[0218] 3) Package chip preparation

[0219] The tablets were compressed using a STYL'One single punch tablet press (14.0 mm shallow concave punch, R=24.75 mm) with a theoretical lower filler of 305 mg and an upper filler of 205 mg. The theoretical total weight of the core was 746 mg, the tablet weight variation was controlled within ±3%, and the tablet hardness was controlled at 170-230N.

[0220] 4) Isolation layer coating

[0221] A 10% concentration of Opadry (YS-1-7027-CN) aqueous solution was prepared as a coating material, which was used as an isolation layer coating solution.

[0222] 5) Immediate release coating

[0223] Weigh the prescribed amount of purified water, slowly add Opadry (03K180007-CN) under stirring and stir for 45 minutes, then add Febuxostat to prepare a solution with a solid content of 12%, stir until evenly dispersed, and use it as the immediate-release layer coating solution.

[0224] 2. In vitro opening central control data of chip-wrapped plain tablets (without isolation layer and quick-release layer)

[0225] In order to ensure that the chip package opens within a certain time in vivo, the opening time in vitro is controlled. The opening time of the chip package is affected by the water absorption speed of the core, so the viscosity of the medium has a greater impact on the opening time. The opening is faster in an aqueous medium and slower in a viscous medium. In order to prevent the chip package from opening too early and failing to achieve the purpose of delayed release, the opening time in an aqueous medium pH4.5PBS-0.5%SDS was investigated; in order to prevent the chip package from opening too late and missing the absorption window, the opening time in a viscous medium pH4.5PBS-2.5%HPMC K100LV (simulating the viscosity and pH of full gastric juice) + 0.1MHCl-3%HPMC E5LV (simulating the viscosity and pH of gastric juice after gastric emptying) was investigated.

[0226] 2.1 Dissolution test in aqueous media

[0227] Table 2. The opening time was investigated in 500 ml of pH 4.5 PBS-0.5% SDS medium using the paddle method at 50 rpm.

[0228]

[0229] 2.2 Dissolution test in viscous media

[0230] The basket method was used at 75 rpm in 500 ml pH 4.5 PBS-2% HPMC K100LV medium for 2 h, and then the medium was changed to 500 ml 0.1 M HCl-3% HPMC E5LV medium for further experimentation. The opening time in the viscous medium was investigated. After changing the medium, the chip was observed every 30 min.

[0231] Table 3.

[0232]

[0233] 2.3 In vitro dissolution data of febuxostat tablets:

[0234] According to the dissolution and release determination method (Chinese Pharmacopoeia 2015 Edition Part IV General Rules 0931 Second Method), use 500 ml of 2.5% HPMC K100LV-pH6.0 phosphate buffer as the dissolution medium, the temperature is 37±0.5℃, the rotation speed is 150 revolutions per minute, and operate according to the law. Take 5 ml of the dissolution solution after 1h, 2h, 3h, and 4h, respectively, filter, and take the filtrate as the test solution. At the same time, add the same volume of dissolution medium at the same temperature for 1h, 2h, and 3h. After 4 hours, the medium in each dissolution cup was discarded, and 900 ml of pH 6.8 phosphate buffer preheated to 37±0.5°C was added to each dissolution cup. The rotation speed remained unchanged and the operation was continued according to the law. 5 ml of the dissolution solution was taken after 0.5 h, 1 h, 1.5 h, and 2 h, respectively, and the filtrate was taken as the test solution. At the same time, the same volume of dissolution medium was added at the same temperature, and the cumulative dissolution amount (%) was determined by HPLC.

[0235] Table 4.

[0236]

[0237] See attached for specific dissolution curves. Figure 3 With attached Figure 4 .

[0238] 3. Measurement of outer layer thickness

[0239] According to the measurement, the thickness of the outer cladding on the Y-axis is 1.2-1.4mm on one side and 1.7-1.9mm on the other side; the thickness of the outer cladding on the X-axis is about 2mm.

[0240] Example 2, Animal PK Results

[0241] This experiment adopted a double-period crossover experimental design. Twelve male Beagle dogs were divided into two groups and gavaged with 240 mg (60 mg*4 tablets) of Febuxostat tablets and 160 mg (40 mg*4 tablets) of Febuxostat tablets (Febuxostat) respectively. The drug concentration-time changes in Beagle dogs were compared to study the pharmacokinetic behavior of the two.

[0242] After a single oral administration of 240 mg of the test article febuxostat tablets to Beagle dogs, the blood drug concentration first reached a lower peak at about 0.5 h, with a concentration of about 2180 ng / mL, and then decreased. The blood drug concentration increased again at 2.00 h, and reached a higher blood drug concentration peak at about 4490 ng / mL at about 4 h. Then the blood drug concentration gradually decreased with time. The overall peak concentration Cmax was 5340±2350 ng / mL, and the peak time Tmax was 4.00 [0.500, 4.00] h. The area under the drug concentration-time curve AUC INF_obs The total time that the blood drug concentration is higher than 100 ng / mL is 19100±8960h*ng / mL. High 12.3±4.88h

[0243] After a single oral administration of 160 mg of the reference substance Febuxostat tablets (Febuli) to Beagle dogs, the blood drug concentration peaked at around 1.00 [0.250, 1.00] h, and then the blood drug concentration gradually decreased over time, reaching a peak concentration Cmax of 6930 ± 3290 ng / mL. The area under the drug concentration-time curve AUC INF_obs 15700±7680h*ng / mL, the total time that the blood drug concentration is higher than 100ng / mL High 9.86±5.00h, see the attached Figure 5 .

[0244] When Beagle dogs were given a 240 mg dose of the test substance febuxostat tablets by oral gavage and a 160 mg dose of the reference substance febuxostat tablets (Febuli) by oral gavage, the febuxostat sustained-release tablets showed obvious double absorption peaks and a significantly reduced Cmax when the drug system exposure was equivalent. The total time that the average blood drug concentration was maintained at the effective blood drug concentration (>100 ng / mL) was 1.25 times that of the reference substance febuxostat tablets, indicating that clinically, the efficacy of febuxostat tablets is maintained longer and the safety is better.

[0245] Example 3, Preparation of Febuxostat Tablets (Prescription 2)

[0246] Table 5. Composition of Prescription 2

[0247]

[0248] Preparation process reference recipe 1.

[0249] Example 4: Pharmacokinetic study of prescription 2 in healthy humans

[0250] 4.1 Research objectives

[0251] 1) To investigate and compare the pharmacokinetic characteristics and relative bioavailability of a single oral dose of febuxostat tablets (large size: 60 mg, N=12, after a medium-fat dinner) developed by Jiangsu Hengrui Medicine Co., Ltd. and febuxostat tablets (size: 40 mg, N=40, in the morning on an empty stomach) produced by Teijin Pharma Co., Ltd. in healthy Chinese adult subjects.

[0252]

[0253] The results showed that the effective concentration of T preparation (blood concentration ≥ 100ng / ml) was maintained for a significantly longer time after a medium-fat meal in the evening than that of R preparation taken on an empty stomach in the morning.

[0254] Comparative Example 1.

[0255] The prescription in Table 7 was prepared according to the preparation method of Example 1, and the opening time was observed in 500 ml of pH 4.5 PBS-0.5% SDS medium using a paddle method at 50 rpm.

[0256] Table 7.

[0257]

[0258]

[0259] The outer coating of the chip prepared by the above prescription was severely dissolved in an aqueous medium and broke within 1 hour, making it difficult to maintain rigidity and integrity.

Claims

1. A tablet core, comprising a tablet core containing an active drug febuxostat, and a coating layer coated on the tablet core, wherein the tablet core is located in the coating layer, and the thickness of the coating layer on both sides of the tablet core in the Y-axis direction is at least one side less than the thickness of the coating layer in the X-axis direction, and the coating layer contains at least one matrix material, at least one hydrophilic gel skeleton material and 1%-10% of glyceryl behenate, wherein the matrix material is a combination of a polymethacrylic acid polymer, polyvinyl acetate and a mixture of polyvidone, wherein the polymethacrylic acid polymer is selected from Eudragit RLPO and Eudragit RSPO, and the polyvinyl acetate and polyvidone mixture is selected from The hydrophilic gel skeleton material is selected from hydroxypropyl methylcellulose; Eudragit RLPO, Eudragit RSPO, glyceryl behenate and part of hydroxypropyl methylcellulose are granulated and mixed with The remaining hydroxypropyl methylcellulose is mixed and then pressed into the core.

2. The chip package according to claim 1, wherein the maximum diameter of the chip package is 12-16 mm.

3. The chip package according to claim 1, wherein the maximum diameter of the chip package is 13-15 mm.

4. The coated core tablet according to claim 1, wherein the content of Eudragit RLPO and Eudragit RSPO in the coating layer is 50%-90% of the total weight of the coating layer, The content is 5%-40% of the total weight of the coating layer.

5. The coated core tablet according to claim 4, wherein the content of Eudragit RLPO and Eudragit RSPO in the coating layer is 60%-85% of the total weight of the coating layer.

6. The coated core tablet according to claim 5, wherein the content of Eudragit RLPO and Eudragit RSPO in the coating layer is 65%-75% of the total weight of the coating layer.

7. The core tablet according to claim 4, wherein the coating layer The content is 15%-25% of the total weight of the coating layer.

8. The coated core tablet according to claim 4, wherein the content of Eudragit RSPO in the coating layer is 5%-40% of the total weight of the coating layer.

9. According to the coated core tablet of claim 8, the content of Eudragit RSPO in the coating layer is 10%-30% of the total weight of the coating layer.

10. The coated core tablet according to claim 9, wherein the content of Eudragit RSPO in the coating layer is 15%-25% of the total weight of the coating layer.

11. The coated core tablet according to claim 4, wherein the content of Eudragit RLPO in the coating layer accounts for 20% to 80% of the total weight of the coating layer.

12. The coated core tablet according to claim 11, wherein the content of Eudragit RLPO in the coating layer accounts for 30% to 70% of the total weight of the coating layer.

13. The coated core tablet according to claim 12, wherein the content of Eudragit RLPO in the coating layer accounts for 45% to 55% of the total weight of the coating layer.

14. The core tablet according to any one of claims 1 to 13, wherein the core tablet further contains at least one excipient selected from a disintegrant, a filler, a binder, a lubricant, and a colorant, wherein the disintegrant is selected from cross-linked sodium carboxymethyl cellulose, dry starch, low-substituted hydroxypropyl methylcellulose, sodium carboxymethyl starch, and cross-linked polyvinylpyrrolidone; the filler is selected from a water-soluble filler and / or a water-insoluble filler, wherein the water-soluble filler is selected from lactose, mannitol, sucrose, and sorbitol, and the water-insoluble filler is selected from starch, microcrystalline cellulose, calcium sulfate, and calcium hydrogen phosphate; the binder is selected from hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl pyrrolidone, methylcellulose, carboxymethyl cellulose, sodium carboxymethyl cellulose, trehalose, and pullulan; the lubricant is selected from colloidal silicon dioxide, talc, stearic acid, magnesium stearate, calcium stearate, sodium stearyl fumarate, polyethylene glycol, or sodium lauryl sulfate, and the colorant is selected from iron oxide, titanium dioxide, and iron hydroxide.

15. The core tablet according to claim 14, wherein the disintegrant is selected from cross-linked sodium carboxymethyl cellulose; the filler is selected from a combination of lactose and microcrystalline cellulose; the binder is selected from hydroxypropyl cellulose; the lubricant is selected from magnesium stearate; and the colorant is selected from iron oxide.

16. A febuxostat tablet, comprising the core tablet according to any one of claims 1 to 15, and further comprising an immediate-release component of febuxostat.

17. The febuxostat tablet according to claim 16, wherein the coating layer of the core tablet contains a rapid-release drug-containing coating layer of febuxostat.

18. The febuxostat tablet according to claim 17, wherein the coating material of the rapid-release drug-containing coating layer is selected from hydroxypropyl methylcellulose, hydroxypropyl cellulose, polyvinyl alcohol, and gastric-soluble Opadry.

19. The febuxostat tablet according to claim 18, wherein the coating material of the rapid-release drug-containing coating layer is selected from gastric-soluble Opadry.

20. The febuxostat tablet according to claim 18, wherein the coating material of the immediate-release drug-containing coating layer is selected from Opadry 03K180007-CN.

21. The febuxostat tablet according to any one of claims 16 to 20, comprising the following ingredients: Chip Febuxostat Lactose 50%-65%; Microcrystalline cellulose 10%-25%; Cross-linked carboxymethyl cellulose sodium 8%-15%; Hydroxypropyl cellulose 1-5%; Magnesium stearate 1%-5%, based on the total weight of the tablet core; Coating layer Eudragit RSPO 15%-25%; Eudragit RLPO 45%%-55%; Glyceryl behenate 1%-10%; 15%-25%; Hydroxypropyl methylcellulose 8%-15%, based on the total weight of the coating layer.

22. The core-coated tablet according to claim 1 or the febuxostat tablet according to claim 16, wherein the core further comprises a hydrophilic gel skeleton material, the content of which accounts for 1%-20% of the total weight of the core.

23. The core-coated tablet or febuxostat tablet according to claim 22, wherein the content of the hydrophilic gel skeleton material is 2%-10% of the total weight of the core.

24. The core-coated tablet or febuxostat tablet according to claim 22, wherein the content of the hydrophilic gel skeleton material is 3%-8% of the total weight of the core.

25. According to the coated core tablet or febuxostat tablet of claim 22, the hydrophilic gel skeleton material is selected from cellulose derivatives, non-cellulose polysaccharides, natural gums, vinyl polymers or acrylic polymers, the cellulose derivatives are selected from methyl cellulose, hydroxyethyl cellulose, hydroxyethyl methyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, hydroxymethyl cellulose and sodium hydroxymethyl cellulose; the non-cellulose polysaccharides are selected from chitin, deacetylated chitosan and galactomannan; the natural gums are selected from pectin, sodium alginate, potassium alginate, agar, carrageenan, locust bean gum and guar gum.

26. The core-coated tablet or febuxostat tablet according to claim 25, wherein the hydrophilic gel skeleton material is selected from cellulose derivatives.

27. The core-coated tablet or febuxostat tablet according to claim 25, wherein the hydrophilic gel skeleton material is selected from hydroxyethyl methylcellulose, hydroxypropyl cellulose, and hydroxypropyl methylcellulose.

28. According to the core-coated tablet or febuxostat tablet of claim 25, the hydrophilic gel skeleton material is selected from hydroxypropyl methylcellulose.

Citation Information

Patent Citations

  • Novel modified release dosage forms of xanthine oxidoreductase inhibitor or xanthine oxidase inhibitors

    CN103210084A

  • Tripulse release stimulant formulations

    CN107530289A

  • Double-release type calcium polycarbophil granules as well as preparation method and application in livestock and poultry

    CN109010320A

  • Febuxostat controlled release composition and preparation method thereof

    CN109985016A

  • Paliperidone tablet and preparation method thereof

    CN110251475A